全文获取类型
收费全文 | 128078篇 |
免费 | 41293篇 |
国内免费 | 367篇 |
专业分类
耳鼻咽喉 | 1830篇 |
儿科学 | 5305篇 |
妇产科学 | 627篇 |
基础医学 | 25616篇 |
口腔科学 | 6753篇 |
临床医学 | 14461篇 |
内科学 | 28308篇 |
皮肤病学 | 4542篇 |
神经病学 | 18853篇 |
特种医学 | 6136篇 |
外国民族医学 | 1篇 |
外科学 | 15935篇 |
综合类 | 2060篇 |
一般理论 | 8篇 |
预防医学 | 8520篇 |
眼科学 | 1494篇 |
药学 | 11663篇 |
中国医学 | 4599篇 |
肿瘤学 | 13027篇 |
出版年
2024年 | 53篇 |
2023年 | 201篇 |
2022年 | 421篇 |
2021年 | 1930篇 |
2020年 | 6265篇 |
2019年 | 11916篇 |
2018年 | 11496篇 |
2017年 | 12555篇 |
2016年 | 11543篇 |
2015年 | 11479篇 |
2014年 | 11426篇 |
2013年 | 11804篇 |
2012年 | 10954篇 |
2011年 | 10921篇 |
2010年 | 9467篇 |
2009年 | 5950篇 |
2008年 | 6545篇 |
2007年 | 5006篇 |
2006年 | 4724篇 |
2005年 | 4382篇 |
2004年 | 4228篇 |
2003年 | 3910篇 |
2002年 | 3659篇 |
2001年 | 2913篇 |
2000年 | 1631篇 |
1999年 | 469篇 |
1998年 | 187篇 |
1997年 | 192篇 |
1996年 | 123篇 |
1995年 | 115篇 |
1994年 | 96篇 |
1993年 | 86篇 |
1992年 | 77篇 |
1991年 | 79篇 |
1990年 | 65篇 |
1989年 | 58篇 |
1987年 | 51篇 |
1985年 | 278篇 |
1984年 | 393篇 |
1983年 | 272篇 |
1982年 | 276篇 |
1981年 | 247篇 |
1980年 | 209篇 |
1979年 | 227篇 |
1978年 | 174篇 |
1977年 | 101篇 |
1976年 | 166篇 |
1975年 | 138篇 |
1974年 | 94篇 |
1973年 | 85篇 |
排序方式: 共有10000条查询结果,搜索用时 16 毫秒
1.
Louise Danielsson RPT MSc Susanne Rosberg RPT PhD 《Scandinavian journal of caring sciences》2015,29(3):501-509
Although depression is associated to physical discomfort, meanings of the body in depression are rarely addressed in clinical research. Drawing on the concept of the lived body, this study explores depression as an embodied phenomenon. Using a hermeneutic phenomenological approach, the analysis of narrative‐based interviews with 11 depressed adults discloses a thematic structure of an embodied process of an ambiguous striving against fading. Five subthemes elicit different dimensions of this process, interpreted as disabling or enabling: feeling estranged, feeling confined, feeling burdensome, sensing life and seeking belongingness. In relation to clinical practice, we suggest that the interdisciplinary team can focus on enhancing the enabling dimensions, for example through guided physical activities to support the patient to feel more alive, capable and connected. Moreover, we suggest that the treatment process benefits from an increased awareness of the ambiguity in the patient's struggle, acknowledging both destructive and recharging elements of the withdrawing, and the perceived conflict in‐between. 相似文献
2.
3.
4.
Well‐being,health and fitness of children who use wheelchairs: Feasibility study protocol to develop child‐centred ‘keep‐fit’ exercise interventions 下载免费PDF全文
5.
Interprofessional collaboration and communication in nursing homes: a qualitative exploration of problems in medical care for nursing home residents – study protocol 下载免费PDF全文
6.
Sophocarpine attenuates toll‐like receptor 4 in steatotic hepatocytes to suppress pro‐inflammatory cytokines synthesis 下载免费PDF全文
7.
《Vaccine》2016,34(39):4724-4731
Human papillomavirus (HPV) infection is the most common sexually transmitted disease worldwide. HPVs are oncogenic small double-stranded DNA viruses that are the primary causal agent of cervical cancer and other types of cancers, including in the anus, oropharynx, vagina, vulva, and penis. Prophylactic vaccination against HPV is an attractive strategy for preventing cervical cancer and some other types of cancers. However, there are few safe and effective vaccines against HPV infections. Current first-generation commercial HPV vaccines are expensive to produce and deliver.The goal of this study was to develop an alternate potent HPV recombinant L1-based vaccines by producing HPV virus-like particles into a vaccine that is currently used worldwide. Live attenuated measles virus (MV) vaccines have a well-established safety and efficacy record, and recombinant MV (rMV) produced by reverse genetics may be useful for generating candidate HPV vaccines to meet the needs of the developing world.We studied in non-human primate rMV-vectored HPV vaccine in parallel with a classical alum adjuvant recombinant HPV16L1 and 18L1 protein vaccine produced in Pichia pastoris. A combined prime-boost approach using both vaccines was evaluated, as well as immune interference due to pre-existing immunity against the MV.The humoral immune response induced by the MV, Pichia-expressed vaccine, and their combination as priming and boosting approaches was found to elicit HPV16L1 and 18L1 specific total IgG and neutralizing antibody titres. Pre-existing antibodies against measles did not prevent the immune response against HPV16L1 and 18L1. 相似文献
8.
9.
10.
Simeprevir added to peginterferon and ribavirin lessens time with fatigue,depressive symptoms and functional limitations in patients with chronic hepatitis C compared with peginterferon and ribavirin: results from 1161 patients in the QUEST‐1, QUEST‐2 and PROMISE studies 下载免费PDF全文
J. Scott L. Gilles M. Fu E. Brohan C. Panter R. Arbuckle W. Jessner M. Beumont 《Journal of viral hepatitis》2015,22(8):639-650
The value of adding simeprevir (SMV) vs placebo (PBO) to peginterferon and ribavirin (PR) for treatment of chronic hepatitis C virus infection was examined using patient‐reported outcomes (PROs); further, concordance of PROs with virology endpoints and adverse events (AEs) was explored. Patients (n = 768 SMV/PR, n = 393 PBO/PR) rated fatigue (FSS), depressive symptoms (CES‐D) and functional impairment (WPAI: Hepatitis C Productivity, Daily Activity and Absenteeism) at baseline and throughout treatment in three randomised, double‐blind trials comparing the addition of SMV or PBO during initial 12 weeks of PR. PR was administered for 48 weeks (PBO group) and 24/48 weeks (SMV group) using a response‐guided therapy (RGT) approach. Mean PRO scores (except Absenteeism) worsened from baseline to Week 4 to the same extent in both groups but reverted after Week 24 for SMV/PR and only after Week 48 for PBO/PR. Accordingly, there was a significantly lower area under the curve (baseline–Week 60, AUC60) and fewer weeks with clinically important worsening of scores in the SMV/PR group at any time point. Incidences of patients with fatigue and anaemia AEs were similar in both groups, but FSS scores showed that clinically important increases in fatigue lasted a mean of 6.9 weeks longer with PBO/PR (P < 0.001). PRO score subgroup analysis indicated better outcomes for patients who met the criteria for RGT or achieved sustained virological response 12 weeks post‐treatment (SVR12); differences in mean PRO scores associated with fibrosis level were only observed with PBO/PR. Greater efficacy of SMV/PR enabled reduced treatment duration and reduced time with PR‐related AEs without adding to AE severity. 相似文献